Rx Compliance Programs May Be Undermined By Federal Investigations
Federal investigators' increasing use of information gathered through internal investigations may undermine the effectiveness of corporate compliance programs, attorney Steven Kowal of Bell Boyd & Lloyd (Chicago) said
You may also be interested in...
A California law scheduled to take effect July 1 will challenge the pharmaceutical industry's ability to track promotional spending
Corporate compliance officers will make up the next wave of "whistleblowers" in health care fraud cases, Philadelphia Associate U.S. Attorney James Sheehan said at the Food & Drug Law Institute Enforcement & Litigation Conference in Washington, D.C. Sept. 22
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011